INTERVIEW: ViroMed Seeks Partnerships With Active Role
This article was originally published in PharmAsia News
South Korea’s ViroMed, a front runner in gene therapy involving naked plasmid DNA, is searching for global partners for its leading project VM202 but is apparently in no hurry to make a decision. In an exclusive interview, its founder and chief science officer tells PharmAsia News what sort of partnerships it is seeking and the goals it hopes to achieve in the coming years.
You may also be interested in...
ViroMed, which is conducting late phase clinical trials of its gene therapy, VM202, in the US, hopes to emerge as a top global DNA-based gene therapy company. It has a promising pipeline of CAR-T and DNA therapies and has hired a team of global experts to propel its efforts.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.